Released Mar 30, 2023, after the close
10-K filed Mar 30, 2023, 89 days after period end · 0000950170-23-011000
Q4 2022 · 10-K
derived · Computed from the longer spans the company filed.
Revenue—
Net Income-$1.21M-$1.21M derivedN/M vs Q4 2021N/M vs Q3 2022
EPS, diluted—Not derived. Share counts vary by quarter.
Operating Incomederived-$1,218,327N/M
Operating Cash Flowderived-$947,467N/M
What the release said
No earnings release is on file for this quarter. Its figures came with the 10-K.
Same quarter
| Metric | Q4 2022dderived from reported figures | Q4 2021dderived from reported figures | Q4 2020dderived from reported figures |
|---|---|---|---|
| Net Income | -$1.21M | -$3.86M | -$1.62M |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Revelation Biosciences, Inc. · CIK 1810560 · Engraved from SEC EDGAR